NewAmsterdam Current Deferred Revenue from 2010 to 2026
| NAMSW Stock | 25.97 2.79 12.04% |
Current Deferred Revenue | First Reported 2010-12-31 | Previous Quarter 4 M | Current Value 5.7 M | Quarterly Volatility 2.6 M |
Check NewAmsterdam Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NewAmsterdam Pharma's main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 29 M or Interest Income of 29 M, as well as many indicators such as Price To Sales Ratio of 187, Dividend Yield of 0.0 or PTB Ratio of 6.17. NewAmsterdam financial statements analysis is a perfect complement when working with NewAmsterdam Pharma Valuation or Volatility modules.
NewAmsterdam | Current Deferred Revenue | Build AI portfolio with NewAmsterdam Stock |
The evolution of Current Deferred Revenue for NewAmsterdam Pharma provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how NewAmsterdam Pharma compares to historical norms and industry peers.
Latest NewAmsterdam Pharma's Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of NewAmsterdam Pharma over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. NewAmsterdam Pharma's Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NewAmsterdam Pharma's overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
NewAmsterdam Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 4,759,842 | |
| Geometric Mean | 4,368,565 | |
| Coefficient Of Variation | 53.69 | |
| Mean Deviation | 1,718,465 | |
| Median | 3,607,000 | |
| Standard Deviation | 2,555,489 | |
| Sample Variance | 6.5T | |
| Range | 9.4M | |
| R-Value | 0.47 | |
| Mean Square Error | 5.4T | |
| R-Squared | 0.23 | |
| Significance | 0.05 | |
| Slope | 240,185 | |
| Total Sum of Squares | 104.5T |
NewAmsterdam Current Deferred Revenue History
About NewAmsterdam Pharma Financial Statements
NewAmsterdam Pharma investors use historical fundamental indicators, such as NewAmsterdam Pharma's Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in NewAmsterdam Pharma. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 4 M | 5.7 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.